Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided versus empirical chemotherapy in unresectable non-small cell lung cancer

Yong Wha Moon, Joo Hyuk Sohn, Yong Tai Kim, Hyun Chang, Jae Heon Jeong, Young Joo Lee, Chang Joon, Se Kyu Kim, Minkyu Jung, Soojung Hong, Sung Ho Choi, Joo Hang Kim

    Research output: Contribution to journalArticle

    5 Scopus citations

    Abstract

    Background: We retrospectively compared adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided and empirical chemotherapies for unresectable non-small cell lung cancer (NSCLC) in this case-control study. Patients and Methods: Unresectable NSCLC patients receiving ATP-CRA- guided platinum-based doublets as first-line therapy were enrolled as cases (n=27; 14 platinum-sensitive and 13 platinum-resistant patients). Performance status, stage, and chemotherapeutic regimen-matched patients receiving empirical chemotherapy were selected from the retrospective database as controls (n=93) in a case to control ratio of ∼1:3. Results: Response rate and survival (progression-free; overall) in both groups were not significantly different. However, the platinum-sensitive subgroup by ATP-CPA showed a higher response rate than the empirical group (71 versus 38% ; p=0.023) with a trend toward longer progression-free survival (8.7 versus 4.8 months for platinum-sensitive versus empirical; p=0.223) and overall survival (not reached versus 12.6 months for platinum-sensitive versus empirical for p=0.134). Conclusion: ATP-CRA may be helpful in selecting platinum-responsive patients in unresectable NSCLC. We consider that nonplatinum doublets in platinum-resistant patients by ATP-CPA may be a more adapted approach than platinum-based doublets in future clinical trials.

    Original languageEnglish (US)
    Pages (from-to)4243-4249
    Number of pages7
    JournalAnticancer research
    Volume29
    Issue number10
    StatePublished - Oct 1 2009

      Fingerprint

    Keywords

    • Empirical chemotherapy
    • In vitro assay-guided chemotherapy
    • Non-small cell lung cancer

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this

    Moon, Y. W., Sohn, J. H., Kim, Y. T., Chang, H., Jeong, J. H., Lee, Y. J., Joon, C., Kim, S. K., Jung, M., Hong, S., Choi, S. H., & Kim, J. H. (2009). Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided versus empirical chemotherapy in unresectable non-small cell lung cancer. Anticancer research, 29(10), 4243-4249.